These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38341613)

  • 1. A potential bivalent mRNA vaccine candidate protects against both RSV and SARS-CoV-2 infections.
    Wu N; Zhang J; Shen Y; Zhang X; Zhou J; Wu Y; Li E; Meng X; Chuai X; Chiu S; Wang Y
    Mol Ther; 2024 Apr; 32(4):1033-1047. PubMed ID: 38341613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Respiratory Syncytial Virus Vaccine Vectored by a Stable Chimeric and Replication-Deficient Sendai Virus Protects Mice without Inducing Enhanced Disease.
    Wiegand MA; Gori-Savellini G; Gandolfo C; Papa G; Kaufmann C; Felder E; Ginori A; Disanto MG; Spina D; Cusi MG
    J Virol; 2017 May; 91(10):. PubMed ID: 28250126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
    Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
    J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
    Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge.
    Phan SI; Zengel JR; Wei H; Li Z; Wang D; He B
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28747496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection.
    Ao Z; Ouyang MJ; Olukitibi TA; Warner B; Vendramelli R; Truong T; Meilleur C; Zhang M; Kung S; Fowke KR; Kobasa D; Yao X
    J Virol; 2022 Sep; 96(18):e0133722. PubMed ID: 36069551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection.
    Liang B; Munir S; Amaro-Carambot E; Surman S; Mackow N; Yang L; Buchholz UJ; Collins PL; Schaap-Nutt A
    J Virol; 2014 Apr; 88(8):4237-50. PubMed ID: 24478424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats.
    Rostad CA; Stobart CC; Gilbert BE; Pickles RJ; Hotard AL; Meng J; Blanco JCG; Moin SM; Graham BS; Piedra PA; Moore ML
    J Virol; 2016 Aug; 90(16):7508-7518. PubMed ID: 27279612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
    Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
    Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
    Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG
    J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Removal of the N-Glycosylation Sequon at Position N116 Located in p27 of the Respiratory Syncytial Virus Fusion Protein Elicits Enhanced Antibody Responses after DNA Immunization.
    Leemans A; Boeren M; Van der Gucht W; Pintelon I; Roose K; Schepens B; Saelens X; Bailey D; Martinet W; Caljon G; Maes L; Cos P; Delputte P
    Viruses; 2018 Aug; 10(8):. PubMed ID: 30110893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
    Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
    Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H
    Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
    Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal immunization with a helper-dependent adenoviral vector expressing the codon-optimized fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in BALB/c mice.
    Fu YH; He JS; Qiao W; Jiao YY; Hua Y; Zhang Y; Peng XL; Hong T
    Virol J; 2013 Jun; 10():183. PubMed ID: 23742026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Split-Dose Administration Enhances Immune Responses Elicited by a mRNA/Lipid Nanoparticle Vaccine Expressing Respiratory Syncytial Virus F Protein.
    Austin LA; Smith JS; Nahas DD; Danzinger A; Secore S; O'Donnell G; Radcliffe S; Hu S; Perley J; Bett AJ; Gindy ME
    Mol Pharm; 2023 Jan; 20(1):279-289. PubMed ID: 36251490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model.
    Kim E; Okada K; Beeler JA; Crim RL; Piedra PA; Gilbert BE; Gambotto A
    J Virol; 2014 May; 88(9):5100-8. PubMed ID: 24574396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
    Patel N; Massare MJ; Tian JH; Guebre-Xabier M; Lu H; Zhou H; Maynard E; Scott D; Ellingsworth L; Glenn G; Smith G
    Vaccine; 2019 Sep; 37(41):6112-6124. PubMed ID: 31416644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.